Novo Holdings A/S sold COAG
May 4, 2026 · Form 4 insider transaction
Novo Holdings A/S sold 32,695 shares of Hemab Therapeutics Holdings, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Disposed (sell-side)
Shares
32,695
Price
$0.00
Total value
N/A
InsiderNovo Holdings A/S
Role10% owner
SecuritySeries C Preferred Stock
Transaction codeC: Conversion of a derivative
Transaction dateMay 4, 2026
Filing dateMay 6, 2026
Shares owned after0
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.